Nature reports that the NIH will soon unveil a $248 million program to develop new 'electroceuticals,' therapeutic implants that can treat disease by stimulating nerves. "The nervous system is criss-crossing our viscera to control many aspects of our organ function," GlaxoSmitheKline's ($GSK) Kristoffer Famm tells Nature. Report